EGFR and osteosarcoma: The discovery of targetable oncogenes led to the routine molecular testing for gene mutations, such as those genes encoding epidermal growth factor receptor (EGFR) and BRAF V600E, ALK, the rat osteosarcoma (ROS1), FLT3, and IDH1/2 [41, 83].